|
Canada-0-ToolsRenting Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- Transthyretin Amyloidosis (ATTR): Symptoms Treatment
Transthyretin amyloidosis (ATTR) happens when clumps of irregular proteins build up in tissues like your heart and nerves Heart failure is a major complication
- ATTR Amyloidosis: Current and Emerging Management Strategies
Screening strategies, monitoring, and treatment of subclinical ATTR-CA requires further study Perhaps the most important translational triumph has been the development of effective therapies that have emerged from a biological understanding of ATTR-CA pathophysiology
- ATTR Amyloidosis: Symptoms, Treatment, Diagnosis, and More
ATTR amyloidosis is related to the abnormal production and buildup of a specific type of amyloid called transthyretin Here's more on the symptoms, diagnosis, and treatments
- Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC . . .
GDMT: Guideline-directed medical therapy, representing treatment options supported for use by clinical practice guidelines with specific considerations for use in individuals with ATTR-CM
- ATTR Amyloidosis: Everything You Want to Know with Dr. Pankaj Arora
The treatment of AL amyloidosis is directed at control of the plasma cell clone with chemotherapy such as alkylating agents (Melphalan and Cyclophosphamide), steroids, protease inhibitors such as bortezomib (Velcade), immunotherapy with Daratumumab, and sometimes autologous stem cell transplant Treatment of ATTR Amyloidosis
- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy Patisiran, an RN
- Managing ATTR-CM: Your guide to current treatment options
Learn current ATTR-CM treatment options, from heart medications to disease-specific therapies, and how new advances can slow progression
- ATTR Treatment Options | ATTR HCP
Learn about therapeutic options that exist for patients with transthyretin-mediated amyloidosis (ATTR)
- Disease Modifying Therapies for the Treatment of Transthyretin . . . - ICER
The prevalence of transthyretin ATTR-CM is difficult to estimate, given likely underdiagnosis and changes in diagnostic modalities over time However, it's estimated that more than 120,000 U S adults have ATTR-CM, with 5,000 to 7,000 new cases diagnosed each year 1,7 Historically, many individuals with ATTR-CM received no disease-specific treatment and those with hereditary forms could
|
|